Midatech Pharma : Corporate Overview

Midatech Pharma Corporate Overview

18 June 2020

Disclaimer

The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by Midatech Pharma PLC (the "Company") in connection with a proposed offering of securities of the Company (the "Offering"). The information in the Presentation is not intended to form the basis of any contract.

The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful.

The distribution of this Presentation may, in certain jurisdictions, be restricted by law. Persons in possession of this Presentation are required to inform themselves about and to observe any such restrictions. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of any documents or any amendment or supplement thereto (including but not limited to this Presentation) in any country or jurisdiction where specific action for that purpose is required.

This Presentation does not constitute an offer or solicitation to purchase or subscribe for securities in the United States. The securities of the Company to which the Presentation relates have not been registered, and will not be registered, under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. Accordingly, any offer or sale of securities in the Company will only be offered or sold (i) within the United States to "qualified institutional buyers" or "accredited investors" (each as defined under the Securities Act) in a private placement transaction not involving a public offering and (ii) outside the United States in offshore transactions in accordance with Regulations S of the Securities Act. Neither the U.S. Securities and Exchange Commission, nor any other United States authority, has approved this Presentation. There will be no public offering of securities in the United States.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company and/or the Offering. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. In furnishing the Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update the Presentation or to correct any inaccuracies in, or omissions from the Presentation which may become apparent. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances, not historical facts and are sometimes identified by the words "believes", expects", "predicts", "intends",

"projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation (including assumptions, opinions and views of the Company or opinions cited from third party sources) are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any officers, directors, or employees of the Company provides any assurance that the assumptions underlying such forward-looking statements are free from errors, nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments described herein. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates or projections. No statement in the Presentation is intended as a profit forecast or a profit estimate.

AN INVESTMENT IN THE COMPANY INVOLVES RISK. SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE PREDICTED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, THE ACTUAL RESULTS OF THE COMPANY MAY VARY MATERIALLY FROM THOSE FORECASTED IN THIS PRESENTATION.

This Presentation and its contents are confidential and you and your directors, officers, employees, agents and affiliates must hold this Presentation and any oral information provided in connection with this Presentation in strict confidence. This Presentation must not be distributed, published, copied or reproduced (in whole or in part) or disclosed by recipients, directly or indirectly, to any other person.

Corporate Overview

• • Drug delivery biotechnology company with disruptive proprietary micro and nano technology platforms

• • Rapid R&D innovation core to success, delivering First-in-Class sustained / modified release therapeutics

• • Dual-listed on AIM and NASDAQ

• • Headquarters, R&D, non-GMP pilot scale manufacturing in Cardiff, UK

• • Approximately 20 employees

Technologies that Make Medicines Better

Technologies focussed on improving bio-delivery and bio-distribution of existing agents

Across all platforms:

• • Successful clinical translation

• • Ongoing clinical programmes

• • Multiple opportunities beyond current programmesQ-Sphera™

MidaSolve™

Sustained Delivery

• • Precision Clinical performance

• • Advanced technology manufacturing

• • Distinct competitive advantage

Local Delivery

• • Converts oral meds into liquid meds

• • Increases routes of administration

• • Enables direct to tumour injection

Q-Sphera™

Next Generation Microsphere Technology for Sustained Release Applications